Brief Summary
This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells or radiation therapya treatment that uses controlled doses of radiation to damage or kill cancer cells, for people with advancedat a late stage, far along or spreading solid tumors. The main objective is to identify the highest tolerable dosethe amount of medication taken or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.
Intervention / Treatment
- Drug: BGB-24714
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Docetaxel
Inclusion Criteria
- Participants must sign a written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. form (ICF); and agree to comply with study requirement
- Phase 1a (Dose Escalation):Part A, A-CN, and B: Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumor previously treated with standard systemic therapy or for whom treatment is not available or not tolerated Note: Only Chinese participants will be eligible for Part A-CN.Part C: Participant has histologically or cytologically confirmed, locally advanced, unresectable Stage III Non-small cell lung cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (NSCLC) suitable for definitive chemoradiotherapy (CRT)Part D: Participant with locally advanced, histologically confirmed inoperable esophageal squamous cell carcinomacancer arising from tissues that line organs (ESCC) suitable for definitive CRTPhase 1b (Dose Expansion): Participants with histologically or cytologically confirmed solid tumors of selected types previously treated with standard therapy.
- Participants must be able to provide formalin-fixed paraffin embedded (FFPE) tumor tissuea group of cells that work together to perform a function sample.
- Phase 1a Part A, A-CN, B and Phase 1b: ≥ 1 measurable lesion per Response evaluation criteria in solid tumors (RECIST) v1.1
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) Performance Status ≤ 1